Immune Biosolutions Receives C$13.44 Million to Develop and Biomanufacture its Promising Immunotherapy to Treat COVID-19 and its Variants

Immune Biosolutions, an innovative biotechnology company, receives $13.44M from the Government of Canada’s Strategic Innovation Fund (SIF) to develop its promising immunotherapy whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants.

This funding will allow the immunotherapy currently in pre-clinical studies to progress to Phase II clinical trials. In addition, Immune Biosolutions will build a biomanufacturing capacity to accelerate the preclinical and clinical development of its therapeutic antibodies.

Immunotherapy is complementary to vaccination. It will be an additional tool for healthcare professionals to treat and control COVID-19.

A Promising Treatment

For over a year, Immune Biosolutions has collaborated with several private and public Canadian organizations to accelerate the discovery, development and biomanufacturing of a novel immunotherapy targeting COVID-19 and its variants. The Sherbrooke-based biotech has identified more than 100 unique anti-SARS-CoV-2 antibodies from convalescent human patients and immunized chickens.

Of these antibody candidates, Immune Biosolutions is currently in preclinical validation with those that have demonstrated the greatest therapeutic potential. Once administered to diagnosed patients, the antibodies discovered by Immune Biosolutions will neutralize the SARS-CoV-2 virus and its variants and accelerate its elimination by the patient’s immune system.